Thomas Stinchcombe

Positions:

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1995

University of Virginia School of Medicine

Internal Medicine Residency

University of Michigan at Ann Arbor

Hematology/Oncology Fellowship

University of North Carolina at Chapel Hill School of Medicine

Grants:

ADXS-503

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

DF/HCC: 17-540

Administered By
Duke Cancer Institute
Awarded By
Dana Farber Cancer Institute
Role
Principal Investigator
Start Date
End Date

TOP 1703

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

MP0250

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Tesaro 3000

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

INTRODUCTION: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied. MATERIALS AND METHODS: We treated 25 patients with EGFR mutant NSCLC on erlotinib who had 3 or fewer sites of extra-cranial progression with SRT to progressing sites, followed by re-initiation of erlotinib. RESULTS: Median PFS from the initiation of SRT was 6 months (95% CI 2.5 to 11.6) and median OS was 29 months (95% CI 21.7 to 36.3). Neither baseline nor changes in the Veristrat proteomic predicted PFS. CONCLUSIONS: SRT and TKI continuation may be considered for select patients with EGFR mutant NSCLC and oligo-progression on EGFR TKI therapy.
Authors
Weiss, J; Kavanagh, B; Deal, A; Villaruz, L; Stevenson, J; Camidge, R; Borghaei, H; West, J; Kirpalani, P; Morris, D; Lee, C; Pecot, CV; Zagar, T; Stinchcombe, T; Pennell, N
MLA Citation
Weiss, Jared, et al. “Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.Cancer Treat Res Commun, vol. 19, 2019, p. 100126. Pubmed, doi:10.1016/j.ctarc.2019.100126.
URI
https://scholars.duke.edu/individual/pub1373701
PMID
30852467
Source
pubmed
Published In
Cancer Treatment and Research Communications
Volume
19
Published Date
Start Page
100126
DOI
10.1016/j.ctarc.2019.100126